Weight-loss drugs: The promise, price and pitfalls, Pg13

Key Highlights:

• Modern anti-obesity drugs like semaglutide and tirzepatide can achieve 15-20% weight loss, comparable to bariatric surgery.
• Recent BMJ reviews confirm their efficacy and cardiovascular benefits but highlight concerns regarding muscle loss and weight regain.
• These medicines cause significant reduction in lean body mass, a particular concern for India's population with lower skeletal muscle mass.
• Patients typically regain weight at an average of 0.4 kg per month after discontinuing medication, often returning to baseline within 1.5-1.7 years.
• The article emphasizes that obesity is a chronic, relapsing disease requiring long-term management, similar to hypertension or diabetes.
• Long-term treatment costs, even with generic versions, pose a significant challenge for India's healthcare system and individuals.

Detailed Insights:

• The BMJ systematic reviews involved nearly 100,000 participants across 262 clinical trials, assessing drug efficacy and cardiovascular outcomes.
• Despite substantial weight loss, improvements in quality of life were found to be modest, not meeting accepted clinical significance thresholds.
• Tirzepatide and semaglutide lead to significant muscle loss, which is crucial for strength, mobility, metabolic health, and healthy aging.
• In India, lower skeletal muscle mass makes individuals more susceptible to increased risks of frailty, falls, disability, and hospitalization due to muscle loss.
• Effective prescription of these drugs requires accompanying advice on adequate protein intake, regular resistance exercise, and periodic muscle strength assessment.
• After stopping treatment, cardiometabolic benefits, including improvements in blood sugar, blood pressure, and cholesterol, also gradually disappear.
• India's obesity strategy must integrate these medicines with broader public health measures like a healthier food environment, physical activity, and public prevention.

Key Concepts Involved:

• Obesity: A complex medical condition characterized by excessive body fat accumulation that may impair health.
• Semaglutide: A glucagon-like peptide-1 (GLP-1) receptor agonist used for type 2 diabetes and chronic weight management.
• Tirzepatide: A dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist for type 2 diabetes and weight management.
• Sarcopenia: The progressive and generalized loss of skeletal muscle mass and strength, often associated with aging.